Patients with heart failure (HF) with preserved ejection fraction (HFpEF) who presented for this study analysis with normal levels of N-terminal prohormone B-type natriuretic peptide (NT-proBNP) and ...

Please provide your email address to receive an email when new articles are posted on . Cancer survivors with increased NT-proBNP levels had an elevated risk for all-cause and cardiac mortality.

Elevated levels of N-terminal pro–B-type natriuretic peptide (NT-proBNP), a key biomarker for diagnosing heart failure, show a nearly fourfold increased risk for atrial fibrillation (AF) in at-risk ...

NT-proBNP is a cornerstone biomarker in the diagnosis and management of heart failure. Despite its widespread use, important biological and analytical challenges remain. One of the most sign ...

Please provide your email address to receive an email when new articles are posted on . Empagliflozin was safe and effective in patients with HF with reduced ejection fraction regardless of systolic ...

In people with no history of CV disease, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels can predict a higher risk of developing CV disease across various blood pressure and pulse pressure ...

In patients with heart failure (HF) and reduced ejection fraction (HFrEF), the copper chelator trientine reduced NT-proBNP levels up to 8 weeks by restoring normal intracellular copper. In models of ...

In this new subanalysis of data from the Atherosclerosis Risk in the Communities study, investigators assessed the risk of incident heart failure (HF) or death by race and sex, as influenced by ...

NT-proBNP testing should become compulsory for referring patients to specialist heart failure services to improve diagnosis, ...